- press release and about Dr. reddy's laboratories in india
- Dr. Reddy’s Q2 FY10: Revenues at Rs. 18,368 million, up by 14%; EBITDA at Rs. 3,797 million, up by 51%;PAT at Rs. 2,173 million, up by 106%
- Dr. Reddy's joins American Chemical Society Green Chemistry Institute® Pharmaceutical Roundtable
- Dr. Reddy's to release Q2 FY10 results on Oct 23, 2009; Earnings call slated for Oct 23, 6.00 PM IST / 8.30 AM EST
- Dr. Reddy’s launches Strea™ C10 and Strea™ A15 in India
Dr. Reddy's offers an unparalleled portfolio to our customers, who include innovators and generic formulators worldwide. With a strong product portfolio of more than 140 products, including niches like oncology and hormones, and our “first in, last out” approach, it is little wonder we are today the third ranked API player globally. Our goal is always to enable our customers to be the first to launch a generic product and to provide value added services to help them remain competitive and profitable for the entire life cycle of the product. We have built the capabilities to consistently deliver on this promise in scale and across the largest product range.services of Dr.reddys
A highly skilled global team focuses on timely delivery of products, product development, technology leadership, cost competitiveness, the highest levels of customer service, and full compliance with regulatory and quality requirements.Present research of reddys
Our expertise in organic synthesis and process development complemented by a controlled supply chain enables us to provide our customers with high quality Bulk Actives at competitive prices. We are aggressively building our product portfolio to cater to generic players in the emerging markets and generic and patent challenge formulators in regulated markets.
Our operations capabilities are among our core strengths, with six USFDA approved plants in India, one in Mexico and our latest addition, a USFDA inspected plant in Mirfield, UK, having a total capacity of 3300KL.wikipedia
Our API business is supported by our technologically advanced Product Development infrastructure, which identifies new products and is engaged every step of the way, from the conceptual stage to delivery of drugs to the market place. The Product Delivery Teams, the Centres of Excellence and IP teams help create value through Intellectual Property and proactive patenting; early development work on certain promising molecules; breakthrough product delivery; and by delivering cost leadership in laboratories
No comments:
Post a Comment